English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Prediction of in vivo drug-drug interactions (DDIs) from in vitro and in vivo data, also named in vitro in vivo extrapolation (IVIVE), is of interest to scientists involved in the discovery and development of drugs. To avoid detrimental DDIs in humans, new drug candidates should be evaluated for their possible interaction with other drugs as soon as possible, not only as an inhibitor or inducer (perpetrator) but also as a substrate (victim). DDI risk assessment is addressed along the drug development program through an iterative process as the features of the new compound entity are revealed. Both in vitro and preclinical/clinical outcomes are taken into account to better understand the behavior of the developed compound and to refine DDI predictions. During the last decades, several equations have been proposed in the literature to predict DDIs, from a quantitative point of view, showing a substantial improvement in the ability to predict metabolism-based in vivo DDIs. Mechanistic and dynamic approaches have been proposed to predict the magnitude of metabolic-based DDIs. The purpose of this article is to provide an overview of the current equations and methods, the pros and cons of each method, the required input data for each of them, as well as the mechanisms (i.e., reversible inhibition, mechanism-based inhibition, induction) underlying metabolic-based DDIs. In particular, this review outlines how the methods (static and dynamic) can be used in a complementary manner during drug development. The discussion of the limitations and advantages associated with the various approaches, as well as regulatory requirements in that field, can give the reader a helpful overview of this growing area.

Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development